Research Spotlight: Basal Cell Carcinoma’s Low Immunogenicity is Associated with Suppression of Antigen Presentation Stemming from its Cell of Origin

Apr 17, 2025

4 minute read

Shawn Demehri, MD, PhD, sitting and smiling with a microscope set on a table next to him — Shawn Demehri, MD, PhD

Shawn Demehri, MD, PhD, a physician-investigator in the Cutaneous Biology Research Center and Krantz Family Center for Cancer Research at Massachusetts General Hospital (MGH) and an Associate Professor of Dermatology at Harvard Medical School, is the senior author of a new study in Cell Reports, "Epigenomic Regulation of Stemness Contributes to the Low Immunogenicity of the Most Mutated Human Cancer". Dr. Demehri is also the Bob and Rita Davis Family MGH Research Scholar 2023–2028.

Summary

Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune-based therapies).

Despite harboring the highest tumor mutational burden of all cancers, basal cell carcinomas (BCCs) have low immunogenicity.

Loss of human leukocyte antigens class I (HLA-I) components is particularly prevalent in immune-excluded cancers.

Tumor antigens are captured and displayed by antigen processing and presentation machinery (APM) on the cell surface by HLA-I, making it possible for CD8+ T cells to eliminate the cancer cells. However, cancer cells have developed various means to limit APM and evade immune recognition.

Tumor cells from basal cell carcinoma patient. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. — Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells.

To determine BCC’s immune state, we studied a large collection of primary human BCCs compared to squamous cell carcinomas (SCCs), which have proven more responsive to immune-based therapies. We discovered that primary BCCs had an immune-excluded phenotype associated with minimal HLA-I expression by cancer cells, even during its early development.

We also determined that a stem-like quiescent program that persisted from the tumor’s cell of origin suppressed APM genes in BCC cells, and that epigenomic reversal of APM gene suppression enabled BCC immunotherapy.

Our findings reveal the cell of origin as the dominant determinant of cancer immunogenicity in BCCs and point to a new approach that could improve treatment.

Background

Keratinocyte carcinoma, including basal cell carcinoma (BCCs) and cutaneous squamous cell carcinoma (SCCs), is the most common cancer with a continuous rise in incidence.

SCCs show a 49.3% objective response rate to PD-1 therapy, while metastatic BCC has only a 21% ORR to anti-PD-1 therapy.

Organ transplant recipients on systemic immunosuppressants have over 100 times higher risk of SCCs compared to the general population but only a 6-16 times higher risk of BCC, suggesting that BCC may lack immunogenicity.

Q: What did you find?

Dr. Demehri: To determine BCC’s immune state, we studied a large collection of primary human BCCs compared with SCCs.

Although T cells were detectable in the stroma surrounding the BCC, significantly fewer CD4+ and CD8+ T cells infiltrated into BCC tumor foci compared with SCCs. A survey of other immune cells found that they were also significantly reduced in BCC compared to SCC.

Single-cell RNA sequencing on BCC and SCC samples collected with similar cell preparation methods showed much smaller immune cell populations in BCC compared to SCC.

These findings indicate that primary BCC has an immune excluded phenotype, which leads to low immunogenicity of BCC compared with “immune infiltrated” SCC.

Importantly, early BCC with rare T cells in the stroma showed low HLA-I expression, indicating that low APM levels in BCC originate from an intrinsic mechanism integral to its developmental biology.

We also found Foxc1 is a critical suppressor of IRF1 and HLA-I in BCC cells, reminiscent of its function in quiescent hair follicle stem cells. Foxc1 downregulates IRF1 and HLA-I expression by epigenomic mechanisms, which can be reversed to enable BCC immunotherapy.

Q: What are the clinical implications?

Dr. Demehri: We demonstrate that topical entinostat treatment upregulates antigen presentation in BCC in vivo. As such, combining entinostat with topical and systemic immunotherapy is key to enabling BCC immunotherapy.

To accomplish this, we combined topical entinostat with an FDA-approved topical immunotherapy, imiquimod. The high efficacy of entinostat plus imiquimod in suppressing BCC development indicates that entinostat-induced APM expression in BCC cancer cells synergizes with immune cell activation by imiquimod to eliminate BCC in vivo.

Based on our findings, a first-in-human clinical trial is warranted to investigate the efficacy of this combination therapy for BCC treatment in humans.

Read the paper

Media contact

Elizabeth Murphy

Program Director, External Communications

emurphy@mgb.org